-
Blog BLOG
-
Product Center BRAND DYNAMICS
-
Investor INVESTOR RELATIONS
-
Contact Us CONTACT
-
Supervise SUPERVISION
High-quality development contributes to the construction of a healthy China. Health Yuan won the title of "2022 China Economic Big Health High-quality Development Enterprise".
Published Time:
2022-12-20
On December 20, 2022, the 2022 China Great Health Industry Summit Forum, hosted by the China Business Journal, concluded successfully. The "2022 Zhongjing Great Health Innovation and Development Exemplary Cases," a highlight of this forum, were announced. After rigorous selection by the judging committee, HealthGen Pharma Group was awarded the "2022 Zhongjing Great Health High-Quality Development Enterprise" title.
Against the backdrop of unprecedented changes in a century and the intertwined impact of the epidemic, health has become a focal point of universal concern. A better life is inseparable from high-quality medical and health services and guarantees, which also places higher demands on the development of the health industry.
Guided by the Healthy China strategy, this forum, together with authoritative experts, scholars, entrepreneurs, and professional institutions, delved into the opportunities and challenges facing the development of China's great health industry, focusing on the theme of innovative development. The forum's case studies focused on four major areas: Traditional Chinese Medicine, biomedicine, digital medicine, and health management, seeking the most innovative and valuable benchmarks in the development of the great health industry and spreading the power of exemplary achievements.
As an innovative research-oriented comprehensive pharmaceutical group company, HealthGen has focused on the great health industry for many years. Based on its mature R&D platform for innovative drugs and high-barrier complex preparations, it has made extensive pipeline layouts in areas with significant clinical needs, such as respiratory, digestive tract, assisted reproduction, mental health, and oncology. It has developed and launched many blockbuster innovative drugs and high-barrier complex preparation products, strongly building the group's diversified product matrix and R&D drug pipeline.
In recent years, HealthGen has launched many high-quality inhalation preparations, gradually breaking through the "bottleneck" development in the sub-sector, becoming the first enterprise in the respiratory drug field to break the international market monopoly. Currently, 7 varieties and 11 specifications of inhalation preparations have been launched, with more than 30 varieties under development. It has successfully achieved coverage of all categories of asthma and COPD inhalation therapies for existing and under-development products, and quickly opened up and covered the domestic market through national negotiations and centralized procurement, winning the title of leader in the domestic high-end inhalation preparation sector.
At the same time, HealthGen has also carried out strategic cooperation with scientific research institutions and innovative companies such as the Chinese Academy of Sciences and Tencent Quantum Laboratory. Guided by clinical value, it is laying out R&D projects with high short-term certainty and cutting-edge technologies with long-term growth potential, such as AI innovative drug molecular design, PROTAC (Proteolysis-Targeting Chimeras), and synthetic biology, to expand its own product matrix and R&D pipeline.
In the face of the COVID-19 epidemic, HealthGen, as a biopharmaceutical enterprise, responded to social needs immediately. After the recombinant COVID-19 virus fusion protein vaccine of its subsidiary, Lizhu Bio, was approved for emergency use as a booster shot by the National Medical Products Administration, it has been used in booster vaccinations in many provinces and cities across the country.
Previously, Guo Bin, academic committee member of Zhejiang University, professor at the School of Management, and director of the Department of Innovation, Entrepreneurship and Strategy, said in an interview with the Shenzhen Business Daily that HealthGen has unique characteristics in breaking down the invisible barriers between research and production. From dedicated cultivation to rapid growth, we look forward to seeing what blockbuster products HealthGen's high-quality development journey will bring in the future!
Quick Navigation
+86 755-33268688 | Service Hotline
Official WeChat Official Account
Copyright © 2025 Joincare Pharmaceutical Group Industry Co., Ltd. ALL Rights Reserve.
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.
These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.
These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.
These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.
Sorry,当前栏目暂无内容!
您可以查看其他栏目或返回 首页
Sorry,The current column has no content!
You can view other columns or return Home